IGFBP7 and left ventricular mass regression: a sub‐analysis of the EMPA‐HEART CardioLink‐6 randomized clinical trial

IGFBP7 and left ventricular mass regression: a sub‐analysis of the EMPA‐HEART CardioLink‐6 randomized clinical trial

Abstract Aims Given recent suggestions that serum levels of insulin‐like growth factor‐binding protein 7 (IGFBP7) may identify patients who derive greater cardiorenal benefits from treatment with sodium‐glucose transport 2 inhibitors (SGLT2i), this exploratory sub‐analysis of the EMPA‐HEART CardioLi...

Full description

Bibliographic Details
Main Authors: Pankaj Puar, Nikhil Mistry, Kim A. Connelly, Andrew T. Yan, Adrian Quan, Hwee Teoh, Yi Pan, Raj Verma, David A. Hess, Subodh Verma, C. David Mazer
Format: Article
Language:English
Published: Wiley 2023-06-01
Series:ESC Heart Failure
Subjects:
IGFBP7
SGLT2 inhibitor
Cardiac reverse remodelling
Left ventricular hypertrophy
Diabetes
Online Access:https://doi.org/10.1002/ehf2.14335

Internet

https://doi.org/10.1002/ehf2.14335

Similar Items